Lung diffusing capacity for nitric oxide and carbon monoxide following mild‐to‐severe COVID‐19
Giovanni Barisione, Vito Brusasco
Abstract
may be present during the recovery from COVID-19, possibly due to loss of alveolar units with alveolar membrane damage, but relatively preserved capillary volume. Alterations of gas transport may be present even in subjects who had mild COVID-19 pneumonia and no or minimal persisting CT abnormalities. TRIAL REGISTRY: ClinicalTrials.gov PRS: No.: NCT04610554 Unique Protocol ID: SARS-CoV-2_DLNO 2020.
Topics & Concepts
DLCODiffusing capacityMedicineInternal medicineLungPulmonary function testingCardiologyRespiratory systemCoronavirus disease 2019 (COVID-19)Lung functionDiseaseInfectious disease (medical specialty)Chronic Obstructive Pulmonary Disease (COPD) ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19